Global vs EU PSMF

Introduction

As pharmaceutical organisations expand internationally, the relationship between global pharmacovigilance governance and regional regulatory requirements becomes increasingly complex.

One of the most common questions asked by QPPVs, pharmacovigilance leaders and consultants is:

Should we maintain a global PSMF, an EU PSMF, or both?

The answer depends on:

• Organisational structure
• Product portfolio
• Geographic footprint
• Outsourcing model
• Governance maturity

There is no universally correct solution.

Each approach carries advantages, disadvantages and inspection considerations.

Understanding these trade-offs is essential when designing a sustainable pharmacovigilance governance model.

Why This Question Exists

The issue arises because pharmacovigilance systems are often global while regulatory requirements are frequently regional.

A company may:

• Use one safety database globally
• Operate one signal management process
• Maintain one quality system
• Use common vendors worldwide

At the same time:

• Regulatory obligations differ
• Local roles differ
• Regional reporting requirements differ
• Regional oversight expectations differ

The challenge is determining how those realities should be documented.

What Is an EU PSMF?

An EU PSMF describes the pharmacovigilance system supporting products subject to European pharmacovigilance requirements.

The document provides regulators with visibility regarding:

• Governance structures
• QPPV oversight
• Processes
• Systems
• Vendors
• Compliance activities

The EU PSMF is fundamentally a regulatory document.

However, mature organisations often use it as a governance tool as well.

For additional information see:

[[what-is-a-psmf]]

What Is a Global PSMF?

A global PSMF is generally not a regulatory requirement.

Instead, it is an organisational document describing the broader pharmacovigilance system across multiple regions.

A global document may include:

• Worldwide governance structures
• Global vendors
• Global systems
• Enterprise-wide processes
• Global oversight mechanisms

The purpose is usually operational consistency rather than regulatory compliance.

The Global-Centric Model

In a global-centric model, the organisation maintains a single primary document describing the overall pharmacovigilance system.

Regional requirements are addressed through supplementary documentation.

Advantages

• Reduced duplication
• Consistent descriptions
• Central governance
• Simplified maintenance

Challenges

• Large document size
• Regional complexity
• Inspection navigation
• Local regulatory differences

Inspectors may find it difficult to identify region-specific information quickly.

The EU-Centric Model

In an EU-centric model, the EU PSMF serves as the primary governance document.

The focus remains on activities relevant to EU regulatory requirements.

Advantages

• Clear regulatory alignment
• Easier inspection use
• Simpler QPPV oversight
• Direct connection to EU requirements

Challenges

• Duplication of information
• Multiple governance documents
• Maintenance burden

This model is common among organisations with significant European operations.

The Hybrid Model

Many multinational organisations adopt a hybrid approach.

A global document provides enterprise-wide governance descriptions.

Regional documents provide local detail.

This often achieves a balance between:

• Consistency
• Compliance
• Maintainability

Hybrid approaches are particularly common in large multinational companies.

Governance Considerations

The choice of model affects governance.

Questions include:

• Who owns the documents?
• How are updates coordinated?
• Which document is authoritative?
• How are inconsistencies prevented?

Poor governance can result in conflicting descriptions across documents.

This creates inspection risk.

Duplication Risk

One of the most significant challenges is duplication.

For example:

• Vendor information
• Organisational charts
• System inventories
• Governance structures

may appear in multiple documents.

The more duplication exists, the greater the risk that documents diverge over time.

Mature organisations actively manage this risk.

Consistency Risk

A common inspection finding involves inconsistencies between documents.

Examples include:

• Different vendor lists
• Different organisational structures
• Different process descriptions

Inspectors may interpret these inconsistencies as evidence of weak governance.

Maintaining consistency therefore becomes a critical objective.

QPPV Oversight Considerations

The chosen model influences QPPV oversight.

Questions include:

• Which document does the QPPV primarily use?
• Which document supports inspections?
• How are regional differences represented?

The stronger the alignment between governance documentation and operational reality, the easier effective oversight becomes.

For additional discussion see:

[[psmf-qppv-oversight]]

Inspection Perspective

Inspectors are generally less interested in the chosen model than in whether it works.

Key questions often include:

• Is the system clearly described?
• Is information accurate?
• Is documentation current?
• Can responsibilities be understood easily?

A simple model implemented well is usually preferable to a sophisticated model implemented poorly.

During Mergers and Acquisitions

Mergers and acquisitions frequently expose weaknesses in documentation models.

Examples include:

• Multiple legacy PSMFs
• Conflicting governance structures
• Duplicate inventories
• Different vendor oversight approaches

A well-designed model can significantly simplify integration activities.

A poor model often creates substantial remediation work.

During Organisational Growth

As organisations expand:

• New affiliates appear.
• New products are added.
• New vendors are engaged.

Documentation complexity increases.

The chosen PSMF architecture should be capable of scaling alongside the organisation.

Characteristics of a Strong Model

Regardless of approach, successful models typically share several characteristics.

Clarity

Users understand which document serves which purpose.

Consistency

Information aligns across documents.

Ownership

Responsibilities are defined clearly.

Maintainability

Updates can be performed efficiently.

Inspection Readiness

Documentation remains usable during inspections.

Which Model Is Best?

There is no universal answer.

A useful rule is:

Small Organisations

Often benefit from simpler approaches.

Medium Organisations

Often benefit from structured EU-centric models.

Large Multinationals

Frequently benefit from hybrid approaches.

The correct choice is the model that best supports:

• Compliance
• Governance
• Oversight
• Inspection readiness

Key Takeaways

• Global and EU PSMFs serve different purposes.
• Global documents support organisational governance.
• EU PSMFs support regulatory compliance and inspections.
• Hybrid models are common among multinational organisations.
• Duplication and consistency represent major governance risks.
• The effectiveness of a model matters more than its complexity.
• Strong governance and clear ownership remain essential regardless of architecture.

References

1. EMA Good Pharmacovigilance Practices (GVP) Module II – Pharmacovigilance System Master File.
2. EMA Good Pharmacovigilance Practices (GVP) Module I – Pharmacovigilance Systems and Their Quality Systems.
3. EMA Good Pharmacovigilance Practices (GVP) Module III – Pharmacovigilance Inspections.
4. Regulation (EC) No 726/2004.
5. Directive 2001/83/EC.
6. Commission Implementing Regulation (EU) No 520/2012.
7. EMA Questions and Answers on Pharmacovigilance System Master Files.